According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

Boehringer Ingelheim reported positive growth in the first half of 2025, with group net sales growing by 6.3%* to EUR 14.0 billion.

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...

Boehringer Ingelheim and SoundTalks end their partnership, but what does this mean for pig farmers? Find out about the future ...

Boehringer Ingelheim's nintedanib has been cleared in the EU to treat lung cancer, just a few weeks after a green light in the US to treat pulmonary fibrosis. The European Medicines Agency (EMA ...

Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

LEO Pharma and Boehringer Ingelheim have entered into a partnership to commercialise and advance the development of ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.